A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202) ☆Original Research Published on 2022-07-082024-09-04 Journal: ESMO open [Category] 대상포진, [키워드] anal cancer clinical trial INCMGA00012 PD-(L)1 inhibitor phase II retifanlimab [DOI] 10.1016/j.esmoop.2022.100529 PMC 바로가기 [Article Type] Original Research